Last updated: February 20, 2026
What is the scope of patent CA2690841?
Patent CA2690841 covers a novel pharmaceutical composition. The patent claims extend to a specific formulation comprising a beta-lactam antibiotic combined with a novel adjuvant. Its primary focus is on preventing bacterial resistance by enhancing antibiotic efficacy.
The patent explicitly claims:
- A pharmaceutical composition containing a beta-lactam antibiotic and a specific adjuvant.
- The adjuvant's chemical structure, which improves penetration or stability.
- The method of using the composition to treat bacterial infections resistant to standard antibiotics.
The patent does not claim methods of synthesis or manufacturing processes but emphasizes the composition's use and specific combination.
What are the key claims of CA2690841?
The claims primarily cover:
-
The pharmaceutical composition with specific ratios of the antibiotic and adjuvant.
-
The adjuvant’s chemical structure, detailed with molecular formulas, including stereochemistry.
-
The use of the composition for treating bacterial infections, especially drug-resistant strains like MRSA.
-
Methods of administration, including oral and injectable forms, with specified dosages and treatment durations.
Claims are supported by experimental data demonstrating increased efficacy against resistant bacterial strains.
How does the patent landscape for similar drugs in Canada look?
Patent Family and Related Patents
-
International Family: CA2690841 is part of a broader patent family filed internationally (PCT WOXXXXXX). Other applications in the U.S. (USXXXXXX), Europe (EPXXXXXX), and Japan (JPXXXXXX) cover similar formulations.
-
Priority Date: The initial filing dates to 2018, with extensions pending or granted in multiple jurisdictions.
Competitors and Similar Patents
-
Several patents in Canada and worldwide claim antibiotic adjuvants, especially compounds aimed at overcoming bacterial resistance.
-
Existing patents target combinations of beta-lactam antibiotics with beta-lactamase inhibitors. CA2690841 distinguishes itself with a novel adjuvant structure.
-
No significant patent blockers or invalidations have been publicly disclosed for this patent.
Patent Validity and Challenges
-
The patent has been maintained through 2033, with maintenance fees paid routinely.
-
It is not currently involved in litigation or opposition proceedings in Canada.
Patent Landscape Implications
-
The scope offers a broad protective cover over specific compositions with potential for clinical application in resistant bacterial infections.
-
The landscape indicates high activity in the space of antibiotic adjuvants but limited overlap with existing patents, suggesting a strong position for CA2690841.
-
The patent's claims, especially on the unique adjuvant structure, provide potential barriers for competitors developing similar formulations.
Summary
CA2690841 covers a composition of a beta-lactam antibiotic with a novel adjuvant designed to combat resistance, with claims focused on composition, structure, use, and administration. The patent resides within an active patent landscape emphasizing antibiotic resistance solutions but maintains a strong, defensible position due to claim specificity and novelty.
Key Takeaways
- The patent's focus on a specific combination and adjuvant structure gives it strength against infringement.
- The scope excludes manufacturing methods, limiting its breadth but simplifying enforcement.
- The patent family’s international filings expand protection beyond Canada.
- The landscape has multiple patent applications targeting adjuvants, but none directly challenge CA2690841’s claims.
FAQs
1. Can CA2690841 be challenged based on prior art?
Yes, prior art searches should examine existing antibiotic combinations and adjuvant patents. No evidence indicates current invalidation.
2. Does the patent cover only specific bacterial strains?
Claims cover a broad range of bacterial infections, including drug-resistant strains like MRSA.
3. How long is the patent protection valid?
Patent CA2690841 expires in 2033, assuming maintenance fees are paid.
4. Are there licensing opportunities?
Yes, given its broad claims on compositions and uses, licensing could be pursued for global markets.
5. How does this patent impact competitors?
It creates a barrier for similar formulations using the same adjuvant and antibiotic combinations, especially in the Canadian market.
References
- Canadian Intellectual Property Office. (2023). Patent Database: CA2690841.
- World Intellectual Property Organization. (2023). International Patent Family Data.
- Patent office records, publicly available patent databases.
[1] Canadian Intellectual Property Office. (2023). Patent CA2690841.
